Morepen Laboratories To Hive Off Medical Devices Business

New Delhi:  Pharmaceutical company Morepen Laboratories Ltd on Tuesday (January 14) said its board has approved the hiving off of its medical devices business to its newly incorporated subsidiary, Morepen Medtech Ltd, on a slump sale basis as a going concern. The transaction is subject to requisite regulatory and shareholder approvals.

“This is to inform that the Board of Directors (the ‘Board’) of the company at their meeting held today i.e., Tuesday, January 14, 2025 (commenced at 5.00 p.m. and concluded at 6.40 p.m.), has, inter-alia, considered and approved the hiving of the Medical Devices Business, being an undertaking, to Morepen Medtech Limited, a subsidiary of the company, on a ‘slump sale’ basis as a going concern,” Morepen Laboratories said in a regulatory filing.

The decision, taken during the board meeting held on January 14, aims to provide operational independence and a concentrated focus on the medical devices segment. Morepen Medtech Limited, incorporated on January 8, 2025, will take over the business upon fulfilment of all conditions precedent.

The Business Transfer Agreement (BTA) is yet to be executed, and the transaction is expected to be completed by September 30, 2025. The consideration for the sale will be determined based on an independent valuation of assets and liabilities in compliance with Rule 11UAE of the Income Tax Rules, 1962.

Morepen Medtech, a subsidiary of Morepen Laboratories, will have an aggregate promoter group shareholding of 20%. The transaction qualifies as a related-party transaction but will be conducted on an arm’s length basis, with requisite member approvals obtained.

Related Posts

  • Pharma
  • July 16, 2025
  • 135 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 43 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients